ClinicalTrials.gg
Not yet recruitingNCT07443644Updated Mar 2, 2026

Targeting Insomnia to Prevent Depression in the Menopause Transition

An interventional study of digital cognitive behavioral therapy for insomnia and Digital sleep hygiene education in Insomnia and Menopause Related Conditions, sponsored by SRI International. Not yet recruiting. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by SRI International · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Study summary

This randomized clinical trial is focused on perimenopausal women who have difficulty sleeping. It will randomize digital cognitive behavioral therapy for insomnia (dCBT-I) or a sleep hygiene intervention (SHI). After treatment, participants will be assessed every 3-months over a 2-year period.

The two main questions the study aims to answer are:

  1. Do participants receiving dCBT-I experience less severe depressive symptoms compared with sleep hygiene (SH) over 2 years of study participation?
  2. Are the effects of dCBT-I on depressive symptom severity mediated by an improvement in insomnia symptoms?
Read the detailed description

Insomnia is a common problem for women in perimenopause. Previous research found that insomnia predicts future development of depression and suggests that treating insomnia can lead to improvement in mood. This study will investigate the long-term effects of treating insomnia with two different interventions on depression among perimenopausal individuals. The two interventions are, digital cognitive behavioral therapy for insomnia (dCBT-I), which has been proven effective, and sleep hygiene intervetion (SHI), which is in common use in general practice.

Participants will be screened for eligibility. Those eligible will be randomized to one of the two treatment arms (dCBT-I or SHI) and complete assessments at 3-month intervals across a 2-year period. Assessments will include questionnaires, clinical interviews, and using a wearable device. All assessments will be done remotely.

Aim 1: To determine if dCBT-I in the menopause transition prospectively prevents depressive symptoms and improves menopause-specific quality of life.

Aim 2: To determine whether the effect of dCBT-I on depressive symptoms is mediated through improving insomnia symptom severity (primary) and secondarily, reducing wakefulness after sleep onset in the menopause transition.

The study will also explore pathways linking dCBT-I and prevention of depressive symptoms.

02

Conditions studied

  • Insomnia
  • Menopause Related Conditions

Keywords

  • menopause
  • hot flashes
  • cognitive behavioral therapy for insomnia
  • insomnia
03

In context

Sleep Initiation and Maintenance Disorders

2,722 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 726 are open to participants now.

This study's planned enrollment of 230 is above the median of 68 across 2,350 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

SRI International is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 40 years old and in the perimenopause,
  2. Willingness to participate in a digital research protocol,
  3. Current moderate to severe insomnia symptoms that started or worsened in association with perimenopause,
  4. English fluency.

Exclusion criteria

Exclusion Criteria:

  1. Current major depressive disorder
  2. Existing diagnosis of a sleep disorder other than insomnia
  3. Experiencing excessive daytime sleepiness
  4. Having received CBT-I in the preceding 6 months
  5. Severe psychiatric or medical conditions or medications that could compromise safe participation in the study or interfere with the scientific aims
  6. Hysterectomy and/or bilateral ovariectomy or current hormonal therapy,
  7. Night shift worker
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Digital cognitive behavioral therapy for insomnia

    An automated digital CBT-I program, delivered in 6 modules at least one week apart.

    Behavioral: digital cognitive behavioral therapy for insomnia

  • Active comparator
    Digital sleep hygiene education

    A digital sleep hygiene intervention delivered in 6 modules, at least one week apart.

    Behavioral: Digital sleep hygiene education

Interventions

  • Behavioraldigital cognitive behavioral therapy for insomnia

    A digital CBT-I program that includes stimulus control, sleep restriction therapy, and cognitive therapy

    Also known as: dCBT-I

  • BehavioralDigital sleep hygiene education

    A digital sleep hygiene education intervention that includes recommendations about environmental and behavioral factors that can support healthy sleep.

06

What researchers measure

Primary outcomes

  1. Depressive symptom severity (PHQ-9 score)

    Time frame: Baseline and every 3 months post randomization for 2 years

  2. Insomnia severity index (ISI)

    Score on the insomnia severity index

    Time frame: Baseline and every 3 months post-randomization for 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2031, 53 months later.

Of 78 industry-sponsored interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 53 months is above that.

Counting every sponsor, half of 1,285 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 2, 2026
StartEst.
Sep 2026
Primary completionEst.
Feb 2031
CompletionEst.
Feb 2031
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443644
Lead sponsor
SRI International
Collaborators
Stanford University
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 2031 (estimated)
Completion
Feb 2031 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion